'Kras mutations' diaporamas de présentation

653 views • 50 slides

Adjuvant and Neoadjuvant Chemotherapy for NSCLC Gregory J. Riely October 14, 2012

Adjuvant and Neoadjuvant Chemotherapy for NSCLC Gregory J. Riely October 14, 2012. Disclosures. Consulting Chugai Ariad Tragara Daiichi Novartis Abbott Foundation Medicine Celgene. Research Funding Novartis Chugai Glaxo SmithKline BMS Infinity Pfizer Merck.

751 views • 50 slides

New Frontiers in Pathology

New Frontiers in Pathology. Case #7 August 3, 2012 Michael H. Roh, MD, PhD University of Michigan Health System. Disclosure Information. The speaker has no relationship representing a possible conflict of interest with respect to the content of this presentation. History.

577 views • 43 slides

Individualizing Therapy for Gastrointestinal Malignancies 2010 Update

Individualizing Therapy for Gastrointestinal Malignancies 2010 Update. Thomas J. Semrad MD, MAS Assistant Professor of Medicine UC Davis Cancer Center. Disclosure. Consulting or Advisory: Genomic Health, Inc. Individualizing Therapy in Colorectal Cancer. Tumor MSI KRAS, BRAF, and others

494 views • 35 slides

How Do You Select Patients for EGFR-targeted Therapy?

How Do You Select Patients for EGFR-targeted Therapy?. Disclosure (Lee M. Ellis). EGF Receptor: Its Role in CRC Therapy. Selecting Patients for Anti-EGFR-Targeted Therapies in CRC. Selection of Patients for EGFR-Targeted Therapies B ased on EGFR- Positivity.

415 views • 26 slides

Development of an EGFR/KRAS testing service for Non-Small Cell Lung Cancer (NSCLC)

Development of an EGFR/KRAS testing service for Non-Small Cell Lung Cancer (NSCLC). Joel Tracey 1 , Caroline Clark 1 , Christine Bell 1 , Keith Kerr 2 , Marianne Nicholson 3 , Aileen Osborne 1 , Zosia Miedzybrodzka 1 , Kevin Kelly 1

544 views • 24 slides

Pharmacogenetics and personalized medicine

Pharmacogenetics and personalized medicine. Tyrosine kinase inhibitors, the P450 cytochromes, TPMT and Warfarin. Pharmacogenetics is generally regarded as the study or clinical testing of genetic variation that gives rise to differing drug responses Pharmacokinetics

461 views • 22 slides

Development of Molecular Methodologies for the Enhanced Detection of Tumour Biomarkers

Development of Molecular Methodologies for the Enhanced Detection of Tumour Biomarkers. Michelle Wood , Hood Mugalassi, Justyna Tull, Linda Meredith, Rachel Butler Institute of Medical Genetics, University Hospital Wales, Cardiff. Lung cancer is the leading cause of cancer deaths.

455 views • 21 slides

Development of Molecular Methodologies for the Enhanced Detection of Tumour Biomarkers

Development of Molecular Methodologies for the Enhanced Detection of Tumour Biomarkers. Michelle Wood , Hood Mugalassi, Justyna Tull, Linda Meredith, Rachel Butler Institute of Medical Genetics, University Hospital Wales, Cardiff. Lung cancer is the leading cause of cancer deaths.

315 views • 21 slides

Mutation Screening of KRAS in FFPE samples using Pyrosequencing

455 views • 18 slides

KRAS testing in colorectal cancer: an overview

KRAS testing in colorectal cancer: an overview. What is KRAS?. KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor (EGFR) signaling pathway This signaling pathway is important in the development and progression of cancer. KRAS and the EGFR pathway.

700 views • 9 slides

Raymond N. DuBois, M.D., Ph.D. Executive Director

Biomarkers for Colorectal Cancer. The National Biomarker Development Alliance Forum March 25, 2013. Raymond N. DuBois, M.D., Ph.D. Executive Director. The Problem.

263 views • 6 slides